ESMO Asia| 乐普PD1+EGFR ADC鼻咽癌2L 67% ORR

文章预览

Preliminary results of phase II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC) Background As an epidermal growth factor receptor-ADC (EGFR-ADC), MRG003, in combination of pucotenlimab (HX008) had shown good tolerability and promising anti-tumor activity in EGFR-positive solid tumors in phase I study. Here we reported the initial results from NPC cohort from the phase II part of HX008/MRG003-C001 (NCT05688605). Methods In this Phase II part, pts with R/M−NPC who had failed first-line platinum-based therapy were enrolled to receive 3.0 mg/kg HX008 combined with 2.0 mg/kg MRG003 every 3 weeks. The primary endpoint was objective response rate (ORR) in full analysis set (FAS) assessed by investigators according to RECIST v.1.1. The secondary endpoint included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safe ………………………………